{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:13:14Z","timestamp":1787026394001,"version":"build-2736575974"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Various causes of recurrent pregnancy loss (RPL) have been identified, but even with a detailed evaluation, almost half of the cases have unidentified etiologies. Immune imbalance is one of the proposed potential etiologies of these idiopathic RPL. To regulate abnormal cellular immunity, intravenous immunoglobulin (IVIG), a type of immunotherapy, is proposed to improve pregnancy outcomes. However, the efficacy of IVIG in RPL is still controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RPL was defined as women with two or more spontaneous abortions and in total, 987 RPL women visited Department of Obstetrics and Gynecology, Konyang University Hospital from January 2007 to December 2020. Only those with a full evaluation and known treatment outcome were included. Idiopathic RPL(n=215) and women with known etiology (n=251) were enrolled. Both the idiopathic and known etiology groups were subsequently stratified into subgroups based on the presence of at least one abnormal cellular immunity (n=100 and n=97, respectively). We investigated the pregnancy outcome by sorting the patients into seven subgroups depending on abnormal cellular immunity including natural killer (NK) cell level, NK cell cytotoxicity and Th1\/Th2 ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with older age and higher body mass index had negative effect on pregnancy outcomes whereas the number of previous miscarriages did not show significant difference in pregnancy outcomes. Among all RPL women with at least one abnormal cellular immunity were treated with IVIG and the overall live birth rate (LBR) was 82.7%. The group which did not have IVIG treatment showed an overall LBR of 80.7%. Among the seven groups of idiopathic RPL women with abnormal cellular immunity, the group with both high NK cell level and NK cell cytotoxicity showed the highest LBR, 90.5%, and the group with both high NK cell level and Th1\/Th2 ratio showed the lowest LBR, 75%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>IVIG treatment appears to improve LBRs in women with RPL and abnormal cellular immunity. These findings support the potential benefit of IVIG in selected RPL patients with immune imbalances. Further studies are needed to refine patient selection criteria and optimize treatment protocols for improving pregnancy outcomes in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1546602","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:14:11Z","timestamp":1748996051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of intravenous immunoglobulin in recurrent pregnancy loss: a retrospective analysis of patients with abnormal cellular immunity"],"prefix":"10.3389","volume":"16","author":[{"given":"Jae Won","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Ki","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","volume-title":"Berek&Novak\u2019s gynecology","author":"Berek","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"101527","DOI":"10.1016\/j.eclinm.2022.101527","article-title":"Intravenous immunoglobulin treatment in women with four or more recurrent pregnancy losses: A double-blind, randomised, placebo-controlled trial","volume":"50","author":"Yamada","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.11.025","article-title":"Definitions of infertility and recurrent pregnancy loss: a committee opinion","volume":"113","year":"2020","journal-title":"Fertil Steril"},{"key":"B4","doi-asserted-by":"publisher","first-page":"hoad002","DOI":"10.1093\/hropen\/hoad002","article-title":"ESHRE guideline: recurrent pregnancy loss: an update in 2022","volume":"2023","author":"Bender Atik","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2012.06.048","article-title":"Evaluation and treatment of recurrent pregnancy loss: a committee opinion","volume":"98","year":"2012","journal-title":"Fertil Steril"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92159-F","article-title":"Recurrent miscarriage","volume":"336","author":"Stirrat","year":"1990","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S100817","article-title":"Recurrent pregnancy loss: current perspectives","volume":"9","author":"El Hachem","year":"2017","journal-title":"Int J Womens Health"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1552586","article-title":"Novel strategies for the management of recurrent pregnancy loss","volume":"33","author":"Kutteh","year":"2015","journal-title":"Semin Reprod Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/medicina60111896","article-title":"Alloimmune causes of recurrent pregnancy loss: cellular mechanisms and overview of therapeutic approaches","volume":"60","author":"Uta","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00321","article-title":"Cellular regulation of the uterine microenvironment that enables embryo implantation","volume":"6","author":"Zenclussen","year":"2015","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.64","article-title":"The unique immunological and microbial aspects of pregnancy","volume":"17","author":"Mor","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12522-015-0207-7","article-title":"NK cell abnormality and its treatment in women with reproductive failures such as recurrent pregnancy loss, implantation failures, preeclampsia, and pelvic endometriosis","volume":"14","author":"Fukui","year":"2015","journal-title":"Reprod Med Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deg156","article-title":"Increased T helper 1 cytokine responses by circulating T cells are present in women with recurrent pregnancy losses and in infertile women with multiple implantation failures after IVF","volume":"18","author":"Kwak-Kim","year":"2003","journal-title":"Hum Reprod"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-0897.2012.01183.x","article-title":"Current trends of reproductive immunology practices in in vitro fertilization (IVF) - a first world survey using IVF-Worldwide.com","volume":"69","author":"Kwak-Kim","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.009","article-title":"The role of immunologic tests for subfertility in the clinical environment","volume":"117","author":"Kwak-Kim","year":"2022","journal-title":"Fertil Steril"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92539-2","article-title":"Preconceptional natural-killer-cell activity as a predictor of miscarriage","volume":"345","author":"Aoki","year":"1995","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13426","article-title":"Functional NK surrogate biomarkers for inflammatory recurrent pregnancy loss and recurrent implantation failure","volume":"86","author":"Comins-Boo","year":"2021","journal-title":"Am J Reprod Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00497.x","article-title":"Immunophenotypic profiles of peripheral blood lymphocytes in women with recurrent pregnancy losses and in infertile women with multiple failed in vitro fertilization cycles","volume":"35","author":"Beer","year":"1996","journal-title":"Am J Reprod Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.5468\/ogs.23120","article-title":"Association of recurrent implantation failure and recurrent pregnancy loss with peripheral blood natural killer cells and interferon-gamma level","volume":"67","author":"Zargar","year":"2024","journal-title":"Obstet Gynecol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103956","DOI":"10.1016\/j.jri.2023.103956","article-title":"Peripheral blood natural killer cell cytotoxicity in recurrent miscarriage: a systematic review and meta-analysis","volume":"158","author":"Cavalcante","year":"2023","journal-title":"J Reprod Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/aji.70060","article-title":"Immune treatment strategies in unexplained recurrent pregnancy loss","volume":"93","author":"Cai","year":"2025","journal-title":"Am J Reprod Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2023.10.042","article-title":"Decrease in peripheral natural killer cell level during early pregnancy predicts live birth among women with unexplained recurrent pregnancy loss: a prospective cohort study","volume":"230","author":"Ou","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/aji.12137","article-title":"Determination of clinical cellular immune markers in women with recurrent pregnancy loss","volume":"70","author":"Lee","year":"2013","journal-title":"Am J Reprod Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0897.2003.00095.x","article-title":"Pre-conceptional natural killer cell activity and percentage as predictors of biochemical pregnancy and spontaneous abortion with normal chromosome karyotype","volume":"50","author":"Yamada","year":"2003","journal-title":"Am J Reprod Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2012.01116.x","article-title":"Th17 and regulatory T cells in women with recurrent pregnancy loss","volume":"67","author":"Lee","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jog.16207","article-title":"Associations of Th1, Th2, Th17, and Treg cell levels and imbalance with recurrent spontaneous abortion: A meta-analysis","volume":"51","author":"Li","year":"2025","journal-title":"J Obstet Gynaecol Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.placenta.2023.08.065","article-title":"The role of Th17 and Treg cells in normal pregnancy and unexplained recurrent spontaneous abortion (URSA): New insights into immune mechanisms","volume":"142","author":"Tang","year":"2023","journal-title":"Placenta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1600-0897.2012.01135.x","article-title":"Intravenous immunoglobulin treatment increased live birth rate in a Spanish cohort of women with recurrent reproductive failure and expanded CD56(+) cells","volume":"68","author":"Moraru","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2017.10.003","article-title":"Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and regulatory T cells in recurrent miscarriage patients: Non randomized, open-label clinical trial","volume":"192","author":"Ahmadi","year":"2017","journal-title":"Immunol Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.v234.6","article-title":"NK cell frequency and cytotoxicity in correlation to pregnancy outcome and response to IVIG therapy among women with recurrent pregnancy loss","volume":"234","author":"Ahmadi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2009.00790.x","article-title":"CD3-CD56+CD16+ natural killer cells and improvement of pregnancy outcome in IVF\/ICSI failure after additional IVIG-treatment","volume":"63","author":"Heilmann","year":"2010","journal-title":"Am J Reprod Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/aji.2016.75.issue-1","article-title":"Intravenous immunoglobulin G improves pregnancy outcome in women with recurrent pregnancy losses with cellular immune abnormalities","volume":"75","author":"Lee","year":"2016","journal-title":"Am J Reprod Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1600-0897.2011.01018.x","article-title":"Elevated preconception CD56 + 16+ and\/or Th1:Th2 levels predict benefit from IVIG therapy in subfertile women undergoing IVF","volume":"66","author":"Winger","year":"2011","journal-title":"Am J Reprod Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"103189","DOI":"10.1016\/j.jri.2020.103189","article-title":"Immunotherapy to improve pregnancy outcome in women with abnormal natural killer cell levels\/activity and recurrent miscarriage or implantation failure: A systematic review and meta-analysis","volume":"142","author":"Woon","year":"2020","journal-title":"J Reprod Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13615","article-title":"Efficacy of intravenous immunoglobulin in the treatment of recurrent spontaneous abortion: A systematic review and meta-analysis","volume":"88","author":"Shi","year":"2022","journal-title":"Am J Reprod Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660506","article-title":"High dose intravenous IgG therapy modulates multiple NK cell and T cell functions in patients with immune dysregulation","volume":"12","author":"McAlpine","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1996.tb00495.x","article-title":"Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions","volume":"35","author":"Kwak","year":"1996","journal-title":"Am J Reprod Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e13739","DOI":"10.1111\/aji.13739","article-title":"ESHRE guideline update 2022: New perspectives in the management of couples with recurrent pregnancy loss","volume":"90","author":"Cavalcante","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dep349","article-title":"Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage","volume":"25","author":"King","year":"2010","journal-title":"Hum Reprod"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1995.tb00960.x","article-title":"Intravenous immunoglobulin for treatment of recurrent pregnancy loss","volume":"34","author":"Coulam","year":"1995","journal-title":"Am J Reprod Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2006.01201.x","article-title":"Use of intravenous immunoglobulin for treatment of recurrent miscarriage: a systematic review","volume":"114","author":"Hutton","year":"2007","journal-title":"BJOG"},{"key":"B42","doi-asserted-by":"publisher","first-page":"CD000112","DOI":"10.1002\/14651858.CD000112.pub3","article-title":"Immunotherapy for recurrent miscarriage","volume":"2014","author":"Wong","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmt056","article-title":"Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis","volume":"20","author":"Seshadri","year":"2014","journal-title":"Hum Reprod Update"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.2012.01178.x","article-title":"Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility","volume":"68","author":"Han","year":"2012","journal-title":"Am J Reprod Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5653\/cerm.2017.44.1.1","article-title":"Intravenous immunoglobulin G in women with reproductive failure: The Korean Society for Reproductive Immunology practice guidelines","volume":"44","author":"Sung","year":"2017","journal-title":"Clin Exp Reprod Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v120.4","article-title":"Intravenous immunoglobulin G treatment increases live birth rate in women with recurrent miscarriage and modulates regulatory and exhausted regulatory T cells frequency and function","volume":"120","author":"Jafarzadeh","year":"2019","journal-title":"J Cell Biochem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13492","article-title":"Maternal and fetal safety of intravenous immunoglobulin in women with reproductive failure","volume":"86","author":"Han","year":"2021","journal-title":"Am J Reprod Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2174\/092986710793176302","article-title":"Genetic factors as a cause of miscarriage","volume":"17","author":"Suzumori","year":"2010","journal-title":"Curr Med Chem"},{"key":"B49","unstructured":"Guideline on the management of recurrent pregnancy loss 2023\n          \n          \n            \n              Goddijn\n              Mari\u00ebtte\n            \n            \n              Christiansen\n              OB\n            \n            \n              Elson\n              J\n            \n            \n              Kolte\n              AM\n            \n            \n              Lewis\n              S"},{"key":"B50","doi-asserted-by":"publisher","first-page":"103346","DOI":"10.1016\/j.jri.2021.103346","article-title":"Menopause is an inflection point of age-related immune changes in women","volume":"146","author":"Han","year":"2021","journal-title":"J Reprod Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(99)00495-1","article-title":"Embryonic karyotype of abortuses in relation to the number of previous miscarriages","volume":"73","author":"Ogasawara","year":"2000","journal-title":"Fertil Steril"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1546602\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:14:12Z","timestamp":1748996052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1546602\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":51,"alternative-id":["10.3389\/fendo.2025.1546602"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1546602","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1546602"}}